Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2024-05-10 Report Publication Anno…
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Audited results for the year ended 31 Dec 2023
Report Publication Announcement Classification · 95% confidence The document is a press release from Shield Therapeutics plc announcing the publication of its audited results for the year ended 31 December 2023, the posting of the Annual Report & Accounts, and the Notice of the Annual General Meeting. It provides financial and operational highlights but explicitly states that the full Annual Report and Accounts are available on the company's website, fitting the definition of a Report Publication Announcement (RPA) rather than the full 10-K report itself. FY 2023
2024-05-10 English
Business Update for Q1 2024
Earnings Release Classification · 99% confidence The document is identified by the RNS Number (4943M) and explicitly states it is being provided via RNS, the news service of the London Stock Exchange. The content provides a 'Business Update for Q1 2024' and confirms 'Key Financials for FY 2023'. This structure—a business update combined with confirmed prior period financials—is characteristic of an Earnings Release (ER) or an Interim Report (IR). However, the text explicitly mentions that the fully audited results for FY23 are expected later (before May 10, 2024), and this announcement serves to provide key metrics and updates for Q1 2024 and confirmed FY2023 highlights. Since it covers both the most recent quarter (Q1 2024) and confirmed prior year financials, it functions as a comprehensive update. Given the options, 'ER' (Earnings Release) is the closest fit for a quarterly business update announcing key financial highlights, even though it also confirms prior year numbers. It is not a full Interim Report (IR) as it explicitly states the audited FY23 results are pending, and it is not a Call Transcript (CT) or Investor Presentation (IP). The presence of the RNS header suggests it is a regulatory announcement, but the content is specific enough to classify it as an ER. Q1 2024
2024-04-30 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4857 characters) released via RNS (RNS Number : 6759K) on April 16, 2024. The title is "Notice of Results Investor Presentation". The text explicitly states that the company "will announce its final results for the year ended 31 December 2023 on Tuesday 30 April 2024" and then details the time and platform for the associated "Investor presentation". According to Rule 2 (The 'MENU VS MEAL' RULE), a short document announcing the publication or details of an upcoming report/presentation is classified as a Report Publication Announcement (RPA). It is not the full Investor Presentation (IP) itself, nor is it the Earnings Release (ER) or Annual Report (10-K), but rather the notice about them.
2024-04-16 English
Unaudited Full Year Trading Update
Earnings Release Classification · 99% confidence The document is titled 'Unaudited Full Year Trading Update' and provides key financial highlights for the full year 2023 (e.g., total revenue, Accrufer revenue, prescription numbers) and Q4 2023. It is explicitly stated to be an 'unaudited trading update' and includes forward-looking statements and contact information typical of a regulatory news service release (RNS Number: 8985D, issued via RNS). This format, focusing on preliminary, high-level results for a period, aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical financial results (key highlights only). Although it is a full-year update, it is not the comprehensive 10-K, nor is it a formal Interim Report (IR) which usually covers half-year or quarterly financials in detail. The document also announces a subsequent investor presentation, but the core content is the financial update itself. FY 2023
2024-02-21 English
Appointment of new Chief Financial Officer
Board/Management Information Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number : 9952Y) on January 9, 2024. The primary subject is the 'Appointment of new Chief Financial Officer'. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific content is not a general regulatory filing or a report publication announcement, but a specific personnel change announcement.
2024-01-09 English
Q3 2023 U.S. Commercial Highlights
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content summarizes 'Q3 2023 U.S. Commercial Highlights' including revenue, prescription growth, and CEO commentary. This structure—a brief announcement of recent operational/financial performance metrics, often released before a full quarterly report—is characteristic of an Earnings Release (ER). However, the document is distributed via RNS and contains the standard RNS footer information, making 'RNS' (Regulatory Filings) a strong candidate as the distribution channel classification. Since the content is a summary of quarterly results (Q3 2023 highlights), it fits the definition of an Earnings Release (ER) better than a comprehensive Interim Report (IR). Given the explicit RNS distribution and the nature of the announcement (highlights, not the full financial statements), classifying it as an Earnings Release (ER) is most appropriate for the content type, although RNS is the distribution mechanism. Since ER is a specific content type, I will prioritize that over the general RNS fallback, as the content is clearly an earnings summary.
2023-12-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.